Craig Lindsley

La Jolla Pharmaceutical Co. and Vanderbilt University have signed a research and license agreement covering Vanderbilt’s research program and intellectual property rights related to compounds that block bone morphogenetic protein (BMP) type-I receptors. The compounds have therapeutic potential in a broad range of diseases, including rare genetic disorders. Read More

Research at Vanderbilt University Medical Center aimed at developing potential new treatments for major depressive disorder, general anxiety disorder and post-traumatic stress disorder got a big boost this week from The William K. Warren Foundation of Tulsa, Oklahoma. Read More

Inhibitors of the enzyme phospholipase D1 suppress the replication of HIV-1, Vanderbilt investigators have discovered. Read More

Vanderbilt University is partnering with the William K. Warren Foundation of Tulsa, Oklahoma, on research aimed at improving the treatment of schizophrenia and other forms of serious mental illness. Read More

Drugs developed at Vanderbilt could provide a new way to treat schizophrenia in a personalized way. Read More

Compounds developed at Vanderbilt University may offer a new way to block influenza infection. Read More

A compound identified at Vanderbilt has therapeutic potential in protecting the kidney filter barrier. Read More

Vanderbilt University’s Craig Lindsley, Ph.D., has won the 2014 John J. Abel Award in Pharmacology for young investigators from the American Society for Pharmacology and Experimental Therapeutics (ASPET). Read More

Vanderbilt University researchers have discovered a “backdoor” approach to blocking an enzyme that fuels the growth of glioblastoma, the most common and most fatal form of brain cancer. Read More

The 2013 Vanderbilt University Medical Center Academic Enterprise Faculty Awards, which were presented during Wednesday’s Spring Faculty meeting, included awards for Excellence in Teaching and Outstanding Contributions to Research. Award recipients were nominated by their faculty colleagues and chosen by the Academic Enterprise Faculty Awards Selection Committee. Read More

Vanderbilt University’s Craig Lindsley, Ph.D., is the 2013 recipient of the Philip S. Portoghese Lectureship, awarded jointly by the Journal of Medicinal Chemistry and the American Chemical Society (ACS) Division of Medicinal Chemistry. Read More

Several Vanderbilt researchers have collaborated with this year's Nobel Chemistry winners. Read More

Vanderbilt University and Bristol-Myers Squibb have signed a collaboration agreement for the discovery, development and commercialization of novel therapies acting on the mGluR4 glutamate receptor, known as positive allosteric modulators, or PAMs, for the treatment of Parkinson’s disease. Read More

Twelve Vanderbilt University faculty members were honored for extraordinary contributions to their respective fields during an Aug. 28 celebration of endowed chair holders at the Student Life Center. Read More

Vanderbilt University has emerged as one of the nation’s leading academic centers in neuroscience. Read More

With the addition of a new 18,000-square-foot laboratory to be located within the Cool Springs Life Sciences Center, Vanderbilt University is expanding its research enterprise into Williamson County. Read More

The progression of new drug candidates for schizophrenia with partner Janssen Pharmaceutica is the latest evidence that a new collaborative model for drug discovery pioneered at Vanderbilt may help identify and develop innovative candidate drugs for treatment of major brain disorders. Read More

Drug-like molecules described by Vanderbilt researchers could lead to Parkinson's treatments with fewer side effects. Read More

The discovery of new compounds that work in a fundamentally different way than those in existing schizophrenia medications may allow for more normal function of brain cells involved in schizophrenia. Read More

Researchers at Vanderbilt University Medical Center, in collaboration with Seaside Therapeutics in Cambridge, Mass., have achieved a milestone in the development of a potential new treatment for fragile X syndrome, the most common genetic cause of autism. Read More